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ABSTRACT
More than 54 million Americans suffer from some form of arthritis and 23.7 million are limited in their usual activity, primarily due to pain. The 
study aims to highlight the concept of Arthralgia and the potential of its management in Unani Medicines. Osteoarthritis (OA) is a slowly progressive 
condition with a variable prognosis. In general, predicting the prognosis in patients with OA is difficult. However, pharmacological therapy can be 
associated with serious side effects and high costs. Therefore, alternative therapies have been under investigation. Herbal medications have shown 
the potential for safe and effective management of arthritis. The Unani Medicine is a rich source of classical knowledge on arthritis. OA has been 
mentioned as Wajaul Mafasil Balghami/Saudawi, and Unani Physicians has been treating this disease successfully with mostly single herbal drugs and 
their compound formulations for centuries. It has been revealed through animal, in vitro, and clinical studies that most of the single and compound 
Unani formulations are safe, without any side effects, and effective in OA, especially gout and rheumatoid arthritis. There is a need to conduct studies 
at Phase III level after analyzing 2nd Phase clinical studies of Unani medicine, so a promising safe, economic, and effective treatment can be provided 
to the ailing society for OA.
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INTRODUCTION
Osteoarthritis (OA) is a long-term chronic disease characterized by the 
deterioration of the cartilage in joints which results in bones rubbing 
together and creating stiffness, pain, and impaired movement. The 
disease most commonly affects the joints in the knees, hands, feet, 
and spine and is relatively less common in the shoulder and hip joints. 
While OA is related to aging, it is also associated with a variety of both 
modifiable and non-modifiable risk factors, including obesity, lack of 
exercise, genetic predisposition, bone density, occupational injury, 
trauma, and gender.
OA is the single most common cause of disability in older adults. The 
prevalence of OA is increasing due to population aging and an increase 
in related factors such as obesity. According to the United Nations, 
by 2050 people aged over 60 will account for more than 20% of the 
world’s population [1].
According to a recent analytical study, the global prevalence of knee 
OA is 16.0% (95% CI, 14.3–17.8%) and the incidence is 95% CI, 106–
331 (203 per 10,000 person-years) [2].
By conservative estimates (between- 2013 and 2015), about 54.4 million 
adults in the U.S. (22.7% of all adults) had doctor-diagnosed arthritis. 
23.7 million (43.5% of those with arthritis) reported activity limitations 
due to their arthritis. There was an increase of about 20% in the number 
of adults with arthritis who reported activity limitations since 2002 [3].
In a recent study, it was concluded that the overall prevalence of 
knee OA is 35.7% (females: 44.5% Males: 23.1%). Age more than 
60 years, female gender, history of trauma, and BMI >30 were found 
to be significantly associated with higher odds of OA knee (p<0.05) in 
Kashmir, India [4].
There is no cure for OA, and no therapy is known to prevent or retard 
the degenerative biological process in articular cartilage. Thus, the 
treatment of OA is focused primarily on relieving symptoms and 
improving function.
TREATMENT
The treatment of arthritis includes non-pharmacologic measures, 
pharmacologic measures, surgery, and protecting cartilage (disease 
modifications) [5].
Non-pharmacological measures
It includes patient education, physical and occupational therapy 
assessment and interventions, exercise, weight loss, and dietary 
measures.
Pharmacologic therapy
NSAIDs are useful in OA mostly for their analgesic effects. In a review 
report it was concluded that concerning pain, results showed that 
NSAIDs provided statistically significant benefits as early as week 
2 (standardized mean difference –0.43, 95% CI, –0.48, –0.38) and 
lasting for up to 26 weeks, however, the effects decreased over time 
and lost clinical significance by 8 weeks. The incidence of minor GI and 
CV AEs consistently rose, reaching significance as early as 4 weeks, 
unfortunately [6].
NSAIDs are associated with hypertension, fluid retention, and 
renal compromise. They are also associated with an increased 
risk of gastric ulcers and bleeding, particularly in patients with a 
history of gastrointestinal disease, those on concomitant steroids or 
anticoagulants, and those older than 65 years [7].
The other therapeutic agent is cyclooxygenase-2 (COX-2)-specific 
NSAID. There is an increased risk of UGIT AEs, especially abdominal 
pain cardiovascular AEs with COX-2 inhibitors, namely, hypertension, 
heart failure, and edema [8]. Celecoxib poses a lesser risk of serious 
gastrointestinal complications than nonselective COX inhibitors [9].
Intra-articular corticosteroid injections may be useful in treating 
selected joints, particularly during exacerbations, and injections in a 
symptomatic knee every 3 months may be a safe and effective means of 
reducing pain and improving function over longer periods [10].
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i2.42218. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
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Intra-articular hyaluronic acid derivatives can be given in a series of 
3–5 weekly injections. In a recent study, it was concluded that IAHA is 
efficacious by 4 weeks, reaches its peak effectiveness at 8 weeks, and 
exerts a residual detectable at 24 weeks [11].
Protecting cartilage (disease modification)
Therapies with the potential to prevent or retard the progression of 
articular cartilage breakdown have received a great deal of attention 
in recent years.
Chondroprotective agents include tetracyclines, protease inhibitors, 
and antiresorptive agents such as bisophosphonates, calcitonin, 
glycosaminoglycan compounds, growth factors, and cytokine inhibitors. 
Oral glucosamine and chondroitin sulfate have been promoted as health 
food supplements to improve cartilage [12].
Glucosamine has low and rare adverse effects, it represents a viable 
option for the management of OA (as a symptomatic slow-acting drug) 
but its administration should be discontinued if no significant effect is 
reported by the patient [13].
Some concerns are raised on the use of oral glucosamine and chondroitin 
sulfate in Diabetic Mellitus patients but clinical studies, including three 
using oral glucosamine, have provided mixed evidence about the effect 
of exogenous glucosamine on glucose metabolism in humans [14].
Surgery
In patients with badly damaged knees and hips, total joint replacement 
is an effective option. Almost all patients experience significant pain 
relief, and some have improved their range of motion. Joint loosening 
and infection are potential late complications in prosthetic joints but 
are uncommon [5].
PROGNOSIS
OA is a slowly progressive condition with a variable prognosis. In 
general, predicting the prognosis in patients with OA is difficult. Risk 
factors for worsening the disease include increased age, increased body 
mass index, proprioceptive deficit, and pain intensity, whereas greater 
muscle strength, mental health, self-efficacy, social support, and aerobic 
exercise are associated with better outcomes [5].
Limitations in the conventional medical management of OA indicate 
a real need for safe and effective treatment of OA patients. Herbal 
medicines may provide a solution to this problem [15].
However, pharmacological therapy can be associated with serious side 
effects and high costs. Therefore, alternative therapies have been under 
investigation. Herbal medications have shown the potential for safe and 
effective management of arthritis.
With the growing interest in herbal therapies among persons with 
rheumatoid arthritis (RA), there exists a need for investigation into 
their safety and efficacy [16].
Unani System of Medicine has a treasure of medical knowledge 
gained through the practice of medicine during its thousands of year’s 
journey. USM treats the disease with a holistic approach with mostly 
safe and time-tested herbal, mineral, and animal origin drugs. I have 
summarized this review explaining the concept and management of 
OA as an attempt to provide economic, safe, and effective alternate 
treatment of OA in Unani Medicine.
WAJAUL MAFASIL IN UNANI MEDICINE
Wajaul Mafasil is an Arabic term composed of Waja meaning pain and 
Mafasil meaning joints. Although Wajaul Mafasil is a symptom of many 
underlying joint diseases, it has been discussed widely in Unani medical 
literature as a disease entity and it is still in use vaguely for arthritis in 
general. For Arthritis the actual terminology in USM is Iltehabe Mafasil.
Historical background
Father of Medicine Hippocrates (460 BC) was the first person to 
document the Wajaul Mafasil in his compendium titled as - Kitabul 
Mafasil. The famous Unani Physician Dioscorides (30–90 AD) also wrote 
on Wajaul Mafasil in his famous book - Kitabul Hashaish (De Materia 
Medica-70AD). Later on Rufus (117AD) also wrote a compendium 
on Wajaul Mafasil known as Kitab Aujawul Mafasil. Jalinoos (Galen 
130 AD) has mentioned Wajaul Mafasil in his book Kitabul Ilaj Wal 
Amraz [17,18]. Razi has described in detail Wajaul Mafasil in Kiatabul 
Hawi vol.11 and also wrote a book on Wajaul Mafasil, namely, Kitab Fee 
Alal-al Mafasil Wa Niqris Wa Irqunnisa [17], Maseehi described Wajaul 
Mafasil in Kitabul Maat in the book number 95 [19].
Definition
Wajaul Mafasil is the term used for pain, inflammation, accumulation, and 
deposition of morbid matters and other disorders of joints. It also includes 
Niqris (Gout), Irqunnisa (Sciatica), and other disorders of joints [20,21].
Samarqandi stated that Wajaul Mafasil is the pain and inflammation 
in organs of joints, that is, Ghazroof (Cartilage), Autar (Tendons), 
Ribatat (Ligaments), Azlat (Muscles), and Ghishae Zulali (Synovial 
Membrane)  [20,22].
ASBAB (ETIOLOGY)
Causes of Wajaul Mafasil are as follows [20].
Asbabe Faila (causative factors)
The factors which affect the joints directly; producing pathological 
changes and joint pain. These are further subdivided into the following.
A. Sue Mizaj
B. Ehtebase Madda
A. Sue Mizaj (deranged temperament)
Kaifiyat (quality or physical properties) of humors is altered. This may 
be of two types.
a. Sazaj/Sada (Simple)
This may be of four types.
i. Sue Mizaj Har Sada (Simple Hot derangement)
ii. Sue Mizaj Barid Sada (Simple Cold derangement)
iii. Sue Mizaj Ratab Sada (Simple Wet derangement)
iv. Sue Mizaj Yaabis Sada (Simple Dry derangement).
b. Sue Mizaj Maddi (Deranged Temperament with Morbid Material) 
kaifiyat (quality) and kammiyat (quantity) of humors is altered. This 
may be of four types.
i. Sue Mizaj Damwi (Sanguineous derangement)
ii. Sue Mizaj Safrawi (Bilious derangement)
iii. Sue Mizaj Balghami (Phlegmatous derangement)
iv. Sue Mizaj Saudawi (Black Bilious derangement).
Wajaul Mafasil Maddi may be due to the following factors.
i. Sue Mizaj Haar Multahib (Hot Inflammatory deranged 
temperament)
ii. Sue Mizaj Barid Munjamid (Cold freezing deranged temperament)
iii. Sue Mizaj Yabis Munqabiz  (Dry constrictive deranged 
temperament) [20,23-26].
B. Ehtebase Madda (Retention of Morbid Matters)
Ibne Sina postulated the theory that when raw humors are accumulated 
in the body and are not excreted out by natural means or induced means 
they got accumulated in joints and causes pathological changes in joints 
and results in Wajaul Mafasil. Accumulated raw humors may be Dam, 
Safra, Balgham, or Sauda. He also mentioned that Reeh (Gas) may be 
accumulated inside joints causing Wajaul Mafasil [20,23,24].
Asbabe Munfaila (predisposing factors)
These factors are not directly responsible for Wajaul Mafasil, but they 
act indirectly in the pathogenesis of Wajaul Mafasil by making the joints 
more prone to get affected by the Asbabe Faila as described above. 
According to Ibne Sina and others, these may be as follows [20].
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i. Irregular diet
ii. Taking water on an empty stomach
iii. Incomplete digestion
iv. Intercourse after taking food
v. Stopping of habitual Istifragh
vi. Lack of exercise
vii. Alcoholism
viii. Excessive Intercourse
ix. Excessive use of joints
x. Treatment of Intestinal colic in the wrong way causing diversion of 
morbid matters to joints
xi. Mental/Psychological stress
xii. Genetic predisposition
xiii. Sex - Males are more prone to be affected than females and eunuchs 
are usually unaffected by Wajaul Mafasil
xiv. Season - Khareef (March-June) followed by Rabee (July-September) 
are favorable seasons for Wajaul Mafasil.
These factors lead to the formation of Fasid Mawad (Morbid 
humors) [20,22-24,26].
CLASSIFICATION
According to the severity of symptoms
1. Wajaul Mafasil Had (Acute Arthralgia)
Severe symptoms develop within a very short duration.
2. Wajaul Mafasil Muzmin (Chronic Arthralgia)
The symptoms are mild with a longer duration [22,24].
According to the temperament of the disease [22,26-32]
1. Haar (Hot)
Temperament of disease is hot as we can feel hotness on palpation of 
the affected joint. It has been further divided into the following.
i. Wajaul Mafasil Damwi
ii. Wajaul Mafasil Safrawi.
2. Barid (Cold)
Temperament of the disease is cold as on palpation, the affected joint is 
felt cold. It has been further divided into the following [24].
i. Wajaul Mafasil Balghami
ii. Wajaul Mafasil Saudawi.
According to the involvement of one or more humor in Wajaul 
Mafasil [22]
1. Wajaul Mafasil Mufrad (Single)
Only one humor is accumulated in joint.
2. Wajaul Mafasil Murakkab (More than One)
There may be an accumulation of more than one humor in the joint.
According to the type of morbid matter accumulated in joints    [20,26]
1. Wajaul Mafasil Damwi
2. Wajaul Mafasil Safrawi
3. Wajaul Mafasil Balghami
4. Wajaul Mafasil Saudawi
5. Wajaul Mafasil Reehi
6. Wajaul Mafasil Ufooni (Infective) [20]
According to the presence of swelling
Akbar Arzani has classified Wajaul Mafasil into the following.
1. Dard Ba Warm (Wajaul Mafasil with swelling)
2. Dard Be Warm (Wajaul Mafasil without swelling) [31].
MAHIYATUL MARZ (PATHOGENESIS)
The pathological changes in the joints take place due to derangement of 
humors which accelerate the process of accumulation of Maddae Fasida 
(altered humors) in the joint space. Ibne Sina further states that;
i. Every movement results in the release of heat. The heat attracts 
Ratoobat (Liquid) which is Maddae Fasida in this case
ii. The cavity in the joint gives space for the accumulation of Ratoobat
iii. Joints consist of cold temperament organs such as bone and cartilage 
which are unable to metabolize accumulated altered humors.
The derangement of the temperament of humors may be simple 
causing Wajaul Mafasil Sada to result in functional disturbance of joints. 
In the case of Sue Mizaj Maddi, there will be an organic disturbance and 
quantitative changes in the joints [20].
ALAMATE MARZ (CLINICAL FEATURES)
Wajaul Mafasil Damwi (sanguinous)
•	 It is a common type of Wajaul Mafasil
•	 The onset is insidious with severe symptoms
•	 Pain in joint on movement leading to restricted movements
•	 Swelling of joints
•	 Tenderness of joints
•	 The skin on the affected joint is reddish
•	 The affected joint is hot on palpation
•	 There will be relief in symptoms on exposure to cold and on taking 
cold temperament things
•	 History of exposure to the factors responsible for Sue Mizaj Damwi.
Wajaul Mafasil Safrawi (billious)
•	 It is a less common type of Wajaul Mafasil
•	 The onset is insidious with severe symptoms
•	 Pain in joint on movement resulting in restricted movements
•	 There may be complaints of itching on the affected joint and all over 
the body
•	 The swelling of joints is lesser than Damwi
•	 Tenderness of joints
•	 The skin on the affected joint is yellowish
•	 The affected joint is hot on palpation
•	 There is relief in symptoms on exposure to cold and on taking cold 
temperament things
•	 There may be a history of exposure to the factors responsible for Sue 
Mizaj Safrawi.
Wajaul Mafasil Balghami (phlegmatous)
•	 It is the most common type of Wajaul Mafasil
•	 The onset is slow with mild to moderate symptoms
•	 Pain increases on movement
•	 There may be mild swelling of the affected joint
•	 Mild tenderness on the affected joint
•	 The skin on the affected joint is whitish and soft
•	 The affected joint is cold on palpation
•	 There will be relief in symptoms on exposure to heat and on taking 
hot temperament things
•	 There may be a history of exposure to the factors responsible for Sue 
Mizaj Balghami.
Wajaul Mafasil Saudawi (black bilious)
•	 It is a rare type of Wajaul Mafasil
•	 The onset is very slow and develops at the last stage of the above-
mentioned types due to metabolic conversion of other humors into 
Sauda with mild to moderate symptoms
•	 Pain increases on movement
•	 Mild tenderness on the affected joint
•	 The skin on the affected joint is black and dry
•	 The affected joint is hard on palpation
•	 There will be relief in symptoms on exposure to cold and on taking 
cold and wet temperament things
•	 There may be a history of exposure to the factors responsible for Sue 
Mizaj Saudawi.
Wajaul Mafasil Reehi (gasious)
•	 The onset is slow.
•	 Pain in joints is shifting in nature [20-31].
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Specific types of Wajaul Mafasil According to the joint affected.
1. Irqunnisa (Sciatic Pain)
2. Niqris (Phalangeal Arthritis/Gout)
3. Wajaul Warik (Pelvic Pain)
4. Wajaul Khasira (Hip Joint Pain)
5. Wajaul Qutn (Low Backache/Lumbago)
6. Wajaul Rakba (Knee Joint Pain)
7. Wajaul Zahr (Backache)
8. Wajaul Mafasil Hudari (RA)
It is chronic and affects multiple joints of fingers, and wrist, it results in 
disfigurement of palm.
9. Wajaul Aqab (Heel Pain)
10. Salabat WA Tahajjur Mafasil (Osteosis/Calcification of Joint)
The affected joint becomes stiff, with no movement and feeling of 
hardness on palpation of the joint [23].
MANAGEMENT OF WAJAUL MAFASIL
1. Taskeen-e-Waja (Relieving of pain)
2. Tahleel-e-Warm (Resolution of Swelling)
3. Tanqiya Mawade Fasida (Cleansing and elimination of morbid matter)
4. Rida-e-Maadda (Diversion of morbid matter)
 When it is not easy to perform Istifragh (Elimination) as mentioned 
above at S.No.3 than Rida-e-Maadda is recommended.
5. Tadeel Sue Mizaj (Correction of deranged temperament)
6. Taqwiyate Mafasil WA Aasab (Strengthening of Joint and Nerves)
Taskeen-e-Waja (relieving of pain)
For immediate relief musakkinat (Analgesics) is given to patients for;
(i) Muqami Istemal (Local application) or (ii) Khurdani Istemal 
(Systemic use) or both.
Tahleel-e-Warm (resolution of swelling)
For this purpose Mohallile Auram (Resolvents/Anti-inflammatory) 
These drugs are prescribed to patients for;
(i) Muqami Istemal (Topical application) or (ii) Khurdani Istemal 
(Systemic use) or both.
Tanqiya Mawade Fasida (cleansing and elimination of morbid 
matter)
For this purpose, various methods are adopted as per the requirement 
of the situation as given below.
i. Idrare Baul (Diuresis)
It is advised in Wajaul Mafasil Muzmin.
ii. Qai (Emesis)
 It is helpful in Wajaul Warik [27].
iii. Munzij Mus-hil Therapy (Concoctive & Purgative)
 This is indicated in Wajaul Mafasil Balghami, Safrawi, and Saudawi, 
Wajaul Mafasil Muzmin.
iv. Hijamah (Cupping)
 For elimination of morbid matter, Hijama bil shurt (Wet Cupping) is 
applied. Sometimes it is applied for the relief of pain also [21].
v. Fasd (Venesection)
For Wajaul Mafasil Damwi, Fasd of the opposite side in ankle and 
foot [3,12] is recommended followed by Qai [11] or Is-hal [24,27].
Rida-e-Maadda (diversion of morbid matter)
When it is not possible to perform Istifragh (Elimination) then Rida-
e-maadda is recommended. Amale Kai (Cauterization) is one of the 
methods recommended for this purpose [20].
Ta’deel Sue Mizaj (correction of deranged temperament)
It is achieved by prescribing medicines of mukhalif kaifiyat/Mizaj 
(opposite temperament) of the predominately affecting humor. It is 
achieved with the use of Munzijat (Concotives), Moaddelat (Alteratives), 
Mus-hilat (Purgatives), Mudirrat (Diuretics), and Mullaiyenat 
(Laxatives).
Taqwiyate Mafasil WA Aasab (strengthening of joint and nerves)




Rest to the patient and affected joint [20,23,24,27,29,30].
DRUGS FOR THE TREATMENT OF WAJAUL MAFASIL
Single drugs
Mainly Musakkinat-e Alam (Analgesics), Murakkhiyat (Muscle relaxant), 
and Mohallilat (Anti-inflammatory) drugs are prescribed as single or 
compound formulations for systemic or local use. Single drugs are 
Suranjan Shirin (Colchicum autumnale), Suranjan Talkh, (Colchicum 
luteum), Gule Babuna (Matricaria chamomile), Gule Surkh (Rosa 
damascena), Asgandh Nagori (Withania somnifera), Ushba Maghribi 
(Smilex aristolochiifolia), Chob Chini (Smilax china), Zanjabil (Zingiber 




 Sufoof-e-Chobchini [38], Sufoof-e-Suranjan, Sufoof-e-Suranjan 
Zafrani [39].
II. Hab (Pills)
 Habbe Asgandh, Habbe Gul-e-Aakh [38], Habbe Azaraqi, Habbe 
Suranjan [38,39].
III. Majoon (Paste)
 Majoon Chobchini Ba Nuskha Khas, Majoon Sowteera [38], Majoon 
Asle Baladur. [39] Majoon Azaraqi, Majoon Chobchini, Majoon 
Falasifa, Majoon Jograj Gugal, Majoon Suranjan, Majoon Lana, Majoon 




Tiryaq-e-Arba, Arq-e-Ajeeb (used as local application as well as 
orally) [34].
For local/topical application
Raughan (Oil): Raughan-e-Auraq, Raughan-e-Bed Anjeer, Raughan-e-
Gul-e-Aakh, Raughan-e-Qust, Raughan-e-Mastagi, Raughan-e-Sarshaf, 
Raughan-e-Shifa [38], Raughan-e-Babuna Qawi Raughan-e-Banafsha, 
Raughan-e-Darchini, Raughan-e-Jauz Buwa,Raughan-e-Jauz Hindi, 
Raughan-e-Malkangni, Raughan-e-Sudab, Raughan-e- Seer, Raughan-e-
Suranjan, and Raughan-e Zaitoon [39] Raughan-e-Azaraqi, Raughan-e-




Suranjan Shirin (C. autumnale)
Suranjan Talkh and Suranjan Shirin have been mentioned in classical texts 
of Unani Medicine for treatment of Wajaul Mafasil but the Talkh variety 
has been advised for external use only due to its toxicity in humans [33]. 
This fact has been proved by the recent research as HPLC profiling 
conclusively distinguished two important Unani drugs, namely, Suranjan 
Shirin (C. autumnale) and Suranjan Talkh (C. luteum). Suranjan Talkh 
contains high alkaloid (Colchicine) contents (0.66%) in comparison to 
Suranjan Shirin (0.33%), so the use of Suranjan Shirin by Unani Physicians 
in human beings for medicinal purposes is due to its low toxicity [40].
In a comparative randomized placebo-controlled study of 100 patients 
with RA, the patients were allocated to the two groups. In Group A, 
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patients were given Sufoof Suranjan (C. luteum) 2 g BD and in Group B, a 
placebo was given similarly. In Group A, CRP became negative but titter 
of the Rh factor reduced to a lower level after treatment of 3 months 
with statistically significant effect in signs and symptoms of RA [41].
Gule Babuna (M. chamomile)
Chamomile contains several phenolic compounds such as apigenin, 
quercetin, patuletin, luteolin, and glucosides. These compounds show 
anti-inflammatory action by reducing cytokines and PGE2, which play a 
role in the pathogenesis of arthritis [42].
In a clinical trial, it was found that daily consumption of 6 g of 
chamomile tea was associated with a reduction in the tenderness of 
joints and erythrocyte sedimentation rate compared to placebo for RA 
patients [43].
Chamomile has been placed on the FDA’s “generally recognized as safe” 
herbs list [44].
Gule Surkh (R. damascena)
In an animal study of the aqua distillate of R. damascena Mill flower, it 
was concluded that Aqua distillate of flower has significant analgesic and 
anti-inflammatory activity at doses of 250 mg/kg and 500 mg/kg [45].
Asgandh (Withania somnifera)
Crude ethanol extract of W. somnifera was studied on peripheral blood 
mononuclear cells of normal individuals and RA patients and synovial 
fluid mononuclear cells of RA patients in vitro. It has been found to 
inhibit the production of TNF-α, IL-1β, and IL-12 by diminishing the 
activation of NF-κB and activator protein 1 signaling pathways [46].
After an in vitro study on aqueous extract of W. somnifera, it was 
concluded that it has a significant chondroprotective effect on 
damaged human OA cartilage via diminishing the gelatinase activity of 
collagenases [47].
In a randomized, double-blind, and placebo-controlled study of Aqueous 
extract of Withania root and leaves on joint pain patients, the higher 
dose (250 mg,) showed efficacy earlier (at 4 weeks), better physician 
global assessments (excellent vs. good vs. fair), and less need for rescue 
medication with paracetamol compared to low dose and placebo [48].
Zanjabil (Z. officinale)
In a randomized double-blind, placebo-controlled study it reported 
that two tablets of 500 mg of ginger daily improved VAS pain scores, 
significantly increased patient satisfaction, and was associated with no 
difference in side effects in comparison to control [49].
In a clinical study, it was found that topical ginger extract in NLC on 
the local application on knee joint significantly improved knee pain, 
stiffness, physical function, and patient global assessments following 
12 weeks of knee OA treatment in comparison to 1% Diclofenac gel 
application [50].
In a randomized comparative study of the effect of manually prepared 
ginger compress and standardized ginger patch on patients of chronic 
OA for 7 days. It was concluded that there was reduction in scores of 
pain, fatigue, global effect, and functional status reduced by 48%, 
49%, 40%, and 31% after 1 week of treatment. After extended period 
of study to 24 weeks, it was concluded that topical ginger treatment 
has the potential to relieve symptoms, improve the overall health, and 
increase independence of people with chronic OA [51].
COMPOUND FORMULATIONS
Majoon Suranjan
In an animal study; it was demonstrated that the antiarthritic efficacy 
of MS was comparable to aspirin in formaldehyde-induced arthritis and 
was superior to aspirin in turpentine oil-induced paw edema and CFA 
induced arthritis [52].
In another animal study, it was concluded that at therapeutic doses, the 
Unani medicine, MS is relatively safe. Furthermore, MS was found to be 
effective in decreasing the biomarkers of RA, thus providing scientific 
evidence in support of its traditional use in the treatment of RA [53].
Habbe Suranjan
In an animal study; it has been concluded that Habbe Suranjan is 
safe  [54].
Habbe Suranjan and Raughan Suranjan
In a recent clinical study of Habbe Suranjan and Raughan Suranjan on 
Arthralgia there was a statistically significant effect on symptoms of 
pain and the drug was safe [55].
Polyherbal formulation of Suranjan Shirin
In a case–control, multicentric, randomized prospective, 2 arm 
parallel-group clinical trial, and results showed that Urinile has the 
potential to decrease serum uric acid level in gouty arthritis patients 
probably because of its antioxidant potential and xanthine oxidase 
inhibitory activity. Polyherbal Herbal formulation Urinile is composed 
of Trachyspermum ammi (Ajwain), Berberis vulgaris (Barberry), C. 
autumnale (Suranjan Shirin), and Apium graveolens (Karafs) [56].
Sufoof-e-Chobchini
In an open-label clinical trial 3.0 g powder of Sufoof-e-Chobchini and 
20 ml syrup of Sharbat-e-Buzoori were given orally to patients twice a 
day after meals for 42 days. 5 ml oil of Raughan-e-Baboona was applied 
locally 2 times a day. Based on this study, it may be concluded that Unani 
compounds drugs Sufoof-e-Chobchini, Sharbat-e-Buzoori, and Roghan-
e-Baboona possess anti-inflammatory, analgesic, and anti-arthritic 
activity for which significant improvement in signs, symptoms were 
observed. The study has also shown that the drugs are non-toxic and 
safe [57].
Majoon Jograj Gugal
In a single group, open clinical study, Majoon Jograj Gugal 5 g bd 
was given to the patients of OA for 8 weeks. After treatment there 
was significant reduction in the VAS Score of all symptoms of OA in 
comparison to baseline VAS Score of the symptoms with reduction of 
ESR to normal level which remained throughout the treatment period. 
It was concluded that the Majoon Jograj Gugal is effective in reducing 
the severity of disease; the drug was well tolerated and did not show 
any side effect [58].
Hijama Bila Shurt (dry cupping)
In a comparative study of the 30 patients of Wajaul mafasil, patients 
were allocated two groups randomly. In Group A of 20, patients were 
advised Habbe Suranjan 2 Pills BD with Hijama Bila Shurt (Cupping) 
for 30 min in a week for 6 weeks. In Group B of 10, patients were given 
Habbe Suranjan 2 Pills BD for 6 weeks only. There was a significant 
effect in subjective parameters of Wajaul Mafasil except for muscular 
weakness in Group A [59].
CONCLUSION
OA is the most commonly occurring disease in the world. It is a known 
fact that there is no cure for OA, and no therapy is known to prevent or 
retard the degenerative process in articular cartilage. There is a risk of 
GI disorders with the known allopathic medications. In this situation, 
Unani Medicine can provide an alternate safe and efficacious therapy.
The clinical features of Wajaul Mafasil are almost the same as described 
for OA in modern medicine with few exceptions. The different types 
of arthritis are almost the same in allopathic and Unani Medicine 
with some new additions which evolved due to advancement in 
scientific tools by understanding the disease on cellular, molecular, and 
biochemical levels.
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OA is a slowly progressing chronic disease of joints of extremities; hence, 
it can be classified as Wajaul Mafasil Balghami/Saudawi according to 
Unani medicine philosophy. This type of disease is treated with hot 
temperament drugs which are Mohallile Auram (Anti-inflammatory) 
and Musakkin Auja (Analgesic) in their pharmacological action [27-29].
The animal, in vitro, and clinical studies of the single and compound 
Unani formulations show that these are safe, without any side effects, 
and effective as mentioned above.
The above-mentioned drugs have been proved to be anti-inflammatory 
and analgesic in their action and are beneficial in OA as described by 
Unani Medicine scholars. It has been proved that Suranjan Shirin in 
single and compound Unani Pharmacopoeial dosage form has been 
effective in arthritis and specifically effective in gout and RA. Similarly, 
Gule Babuna is effective in RA on internal as well on local applications. 
Asgandh has Chondroprotective property. Zanjabeel has been found 
effective in OA on internal as well as topical applications.
Till now some 2nd Phase clinical studies on single/compound drugs 
have been conducted with promising results as mentioned above.
We can improve the efficacy of these drugs with some modifications in 
traditional dosage forms as has been indicated in a recent study. In a 
comparative study of cumulative drug release (CDR) of classical Unani 
Raughan and Unani emulgel, the CDR of Unani emulgel was higher 
78.82% as compared to Unani Raughan 58.64% [60].
Hence, there is a need to conduct studies at Phase III level after 
analyzing 2nd Phase clinical studies, so a promising safe, effective, and 
economic treatment can be provided to the ailing society for OA.
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